Details for Patent: 7,585,897

Which drugs does patent 7,585,897 protect, and when does it expire?

Patent 7,585,897 protects APLENZIN and is included in one NDA.

This patent has fifty-two patent family members in eighteen countries.

Summary for Patent: 7,585,897

Title:	Modified release formulations of a bupropion salt
Abstract:	The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a medicament to treat a condition.
Inventor(s):	Werner Oberegger, Fang Zhou, Paul Maes, Graham Jackson, Mohammad Ashty Saleh
Assignee:	Valeant International Bermuda
Application Number:	US11/766,239
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,585,897
Patent Claim Types: see list of patent claims	Composition; Compound; Dosage form;

error: insufficient information

Drugs Protected by US Patent 7,585,897

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bausch	APLENZIN	bupropion hydrobromide	TABLET, EXTENDED RELEASE;ORAL	022108-001	Apr 23, 2008		RX	Yes	No	7,585,897		Y
Bausch	APLENZIN	bupropion hydrobromide	TABLET, EXTENDED RELEASE;ORAL	022108-002	Apr 23, 2008		RX	Yes	No	7,585,897		Y
Bausch	APLENZIN	bupropion hydrobromide	TABLET, EXTENDED RELEASE;ORAL	022108-003	Apr 23, 2008		RX	Yes	Yes	7,585,897		Y

International Family Members for US Patent 7,585,897

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006261788
Australia	2008285660
Australia	2008320915
Canada	2578626